期刊文献+

药物转运体表观遗传调控机制的研究进展 被引量:4

Research progress on regulation mechanism of epigenetic modifications for drug transporters
原文传递
导出
摘要 药物转运体在体内药物吸收、分布和排泄过程中发挥着重要的作用。转运体在各组织器官的分布和表达受到表观遗传修饰调控,导致某些药物体内处置过程出现明显的个体差异。随着表观遗传学的发展,基于表观遗传修饰(如DNA甲基化、组蛋白修饰、microRNA干预等)调控药物转运体的相关研究越来越多。对表观遗传调控药物转运体研究进行综述。 Drug transporters play a key role in drug absorption, distribution and excretion. The distribution and expression of transporters in tissues and organs are regulated by epigenetic modifications, resulting in individual differences of drugs disposition significantly. With the development of epigenetics, researches on the regulation of drug transporters expression based on epigenetic modifications (DNA methylation, histone modification, microRNA interference, etc.) have been more and more reported. In this paper, we will summarize the epigenetic modifications regulating drug transporters.
出处 《药物评价研究》 CAS 2017年第9期1229-1234,共6页 Drug Evaluation Research
关键词 药物转运体 表观遗传修饰 DNA甲基化 组蛋白修饰 MICRORNA drug transporters epigenetic modifications DNA methylation histone modification microRNA
  • 相关文献

参考文献3

二级参考文献40

  • 1孙进,赵焰平,郝秀华,何仲贵.多药耐药相关蛋白2:在肠道药物处置中的重要作用[J].中国新药与临床杂志,2006,25(10):792-797. 被引量:2
  • 2孙进,陆榕,范晓文,何仲贵.转运蛋白在药物传递中的重要作用[J].中国药学杂志,2007,42(3):164-168. 被引量:1
  • 3Endres C J, Hsiao P, Chung F S, et al. The role of transport ers in drug interactions[J]. Eur J Pharm Sci, 2006, 27 (5): 501-517.
  • 4Szakacs G, Varadi A, Ozvegy-Laezka C, et al. The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox)[J]. Drug Discov Today, 2008, 13(9 10): 379-393.
  • 5Lin JH. Drug-drug interaction mediated by inhibition and in duction of P glycoprotein[J]. Adv Drug Deliv Rev, 2003, 55 (1): 53-81.
  • 6Vallakati A, Chandra PA, Pednekar M, et al. Droncdarone Induced Digoxin Toxicity: New Drug, New Interactions[J]. Am J Ther, 2011.
  • 7Friedrich C, Ring A, Brand T, et al. Evaluation of the pharmacokinetic interaction after multiple oral doses of linagliptin and digoxin in healthy volunteers[J]. Eur J Drug Metab Phar macokinet, 2011, 36(1) : 17-24.
  • 8Shoal SE, Ohzone Y, Ninomiya S, et al. In vitro P-glycopro tein interactions and steady-state pharmacokinetie interactions between tolvaptan and digoxin in healthy subjects[J]. J Clin Pharmaeol, 2011, 51 (5) : 761-769.
  • 9Aylin Arici M, Kilinc E, Demir O, et al. Interactions between Verapamil and Digoxin in Langendorff Perfused Rat Hearts:The Role of Inhibition of P-glycoprotein in the Heart[J]. Basic Clin Pharmaeol Toxieol,2010, 107(5): 847-852.
  • 10Schmitt C, Kaeser B, Riek M, et al. Effect of saquinavir/ ritonavir on P-glycoprotein activity in healthy volunteers using digoxin as a probe[J]. Int J Clin Pharmacol Ther, 2010, 48 (3): 192-199.

共引文献34

同被引文献68

引证文献4

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部